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FOR THE ARPEGGIO STUDY GROUP
OBJECTIVE — To examine the efﬁcacy and safety of rimonabant, a selective cannabinoid
receptor type-1 antagonist, in patients with type 2 diabetes receiving insulin monotherapy.
RESEARCH DESIGN AND METHODS — Patients (n  368; A1C 7%) were ran-
domizedto20mg/dayrimonabantorplacebointhis48-week,double-blind,placebo-controlled
multicenter trial. Change in baseline A1C to week 48 (primary outcome) and changes in body
weight, waist circumference, and lipid levels (secondary outcomes) were assessed.
RESULTS — Rimonabant signiﬁcantly reduced baseline A1C versus placebo (0.89 vs.
0.24%; P  0.0001), and signiﬁcantly greater improvements were observed in cardiometa-
bolic risk factors. More rimonabant patients achieved 10% reduction in mean total daily
insulin dose versus placebo (P  0.0012), and fewer required rescue medication (P  0.0001).
Hypoglycemia,nausea,dizziness,anxiety,anddepressionweremorefrequentwithrimonabant.
CONCLUSIONS — Rimonabant improved glycemic control and cardiometabolic risk fac-
tors in patients with type 2 diabetes receiving insulin.
Diabetes Care 33:605–607, 2010
T
he increasing prevalence of obesity
is contributing to a type 2 diabetes
epidemic (1). Current standard of
care of type 2 diabetes targets control of
lipid and blood pressure levels, as well as
glucose control (1–3). Most classes of an-
tidiabetes agents are associated with
weight gain, spurring research into thera-
peutic agents that improve both weight
andglycemia,alongwithfavorableeffects
on other comorbidities (4).
The endocannabinoid system con-
tributes to energy homeostasis and lipid
and glucose metabolism regulation (5).
Treatment with the selective cannabinoid
type 1 (CB1) receptor antagonist rimon-
abant improves multiple cardiometabolic
risk factors in overweight/obese patients
(6–10) as well as glycemic control in pa-
tients with drug-naïve type 2 diabetes
(SERENADE study) (11) or disease sub-
optimally controlled on sulfonylurea/
metformin (RIO-Diabetes study) (8).
The ARPEGGIO study evaluated
once-daily 20 mg rimonabant on glyce-
mic control in patients with type 2 diabe-
tes inadequately controlled on insulin
monotherapy (a population considered
therapeutically challenging). It should be
noted that the clinical development of
rimonabant has stopped and the com-
pound withdrawn from the market.
RESEARCH DESIGN AND
METHODS— Eligible patients were
aged 18 years, with type 2 diabetes,
screening A1C 7%, and receiving insu-
lin monotherapy for 3 months (30
units/day for 4 weeks). Type 1 diabetes
was excluded with C-peptide 1.0 ng/dl.
Patients with a history of depression
and/or past/current antidepressant treat-
ment were included. Institutional review
boards and independent ethics commit-
tees at each center approved the protocol.
The study was conducted in accordance
with the Declaration of Helsinki. Patients
provided written informed consent.
Following a 14-day screening period,
patients were randomized (1:1; stratiﬁed
by A1C level) to placebo or 20 mg rimon-
abant (oral, once daily before breakfast)
for48weeks.Patientswereadvisedtofol-
low a controlled diet and increase physi-
cal activity. The total daily insulin dose
(TDID) was to be maintained at a stable
level(10%increase/decreaseofbaseline
dose). Use of rescue medication (in-
creased insulin dose, oral medication)
was at the investigator’s discretion if the
patient met certain criteria; such patients
remained in the study.
Primary end point was the change
from baseline to study end (day 336) in
A1C. Secondary end points included
changes in glycemic parameters (fasting
plasmaglucose,patientsmeetingA1C7
and 6.5% targets, introduction of res-
cue medication, and change in mean
TDID [MTDID]), proportion of patients
with decreased TDID (10% of baseline
dose), lipid parameters (HDL cholesterol,
triglycerides, LDL cholesterol, total choles-
terol, and total-to-HDL cholesterol ratio),
body weight, and waist circumference. In
addition to standard safety assessments, a
scripted neurological and psychiatric ques-
tionnaire was completed at each visit (see
online appendix [available at http://care.
diabetesjournals.org/cgi/content/full/dc09-
0455/DC1]).
RESULTS— In total, 366 patients
were randomized (n  179 rimonabant;
n  187 placebo), and 284 completed
treatment (134 [74.9%] rimonabant; 150
[80.2%] placebo). Demographic and
baseline clinical characteristics were sim-
ilar across groups (supplementary Table
1).Atweek48,rimonabantproducedsig-
niﬁcantly greater reductions in A1C and
fasting plasma glucose levels versus pla-
cebo, and signiﬁcantly more patients
achieved target A1C levels (supplemen-
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tinuously with rimonabant without plateau
(Fig. 1A). Within both groups, higher base-
line A1C levels correlated with greater ab-
solute A1C reductions; between-group
differences favored rimonabant within all
baseline A1C categories (Fig. 1B). Rimon-
abant resulted in a signiﬁcantly greater
change in MTDID than placebo (mean dif-
ference 2.90; P  0.0004), and more pa-
tients reduced MTDID by 10%.
Signiﬁcantly fewer patients receiving
Figure 1—A: Change in A1C over time. B: Change in A1C according to baseline level. C: change in body weight over time.
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Days with at least one nonsymptomatic hy-
poglycemic event were greater with rimon-
abant than placebo (2.34 vs. 1.18 days,




ence, HDL cholesterol, triglycerides, and
total-to-HDL cholesterol ratio. No be-
tween-group differences were observed
for total or LDL cholesterol changes. The
overallincidenceoftreatment-emergentad-
verse events (TEAEs) was similar between
groups(supplementaryTable3);therewere
slightly fewer serious TEAEs with rimon-
abant versus placebo. TEAEs were mild to
moderate in intensity, generally occurred
early in treatment, and resolved without
further corrective therapy. Metabolism/
nutritionalandpsychiatricTEAEsoccurred
more frequently with rimonabant than pla-
cebo. Psychiatric disorders occurred in
31.3%ofrimonabant-treatedpatientscom-
pared with 18.7% for placebo. Serious hy-
poglycemia was reported in four
rimonabantpatientsversustwoonplacebo.
CONCLUSIONS — The ARPEGGIO
study showed that 20 mg rimonabant sig-
niﬁcantly reduced A1C levels and im-
proved multiple cardiometabolic risk
factors in patients with type 2 diabetes
receiving various types of insulin mono-
therapy, consistent with clinical trials of
rimonabant in other type 2 diabetes pop-
ulations (8,11).
Similar to previous studies and diabe-
tes pharmacotherapy in general, A1C re-
ductions were greatest in patients with
highestbaselineA1C(12).TheARPEGGIO
study was characterized by a higher mean
baseline A1C than patients in the SERE-
NADE and RIO-Diabetes studies (8,11),
and a larger fall in A1C may have been ex-
pected. The result may have been affected
byweightloss(althoughsigniﬁcantwasless
in this study and may have been mitigated
by larger increases in glysuria) and reduced
insulindosingintherimonabantgroupsec-
ondary to hypoglycemia.
Weight loss was less than that ob-
served in other studies (8,11). Weight gain
is often associated with insulin therapy. In
addition, patients in the ARPEGGIO study
(mean diabetes duration 14 years) were
characterized by advanced -cell loss and
variable insulin resistance. Rimonabant-
induced weight loss occurs through cen-
tral effects in reducing food intake and
through peripheral metabolic pathways
(altered substrate utilization, changes in
adiponectin, and changes in energy ex-
penditure) (13). This study showed that
rimonabant facilitates weight loss in pa-
tients receiving insulin and may indepen-
dently impact glucose, but the absolute
changemaybeattenuatedcomparedwith
nondiabetic patients or those receiving
oral agents.
The safety proﬁle of rimonabant was
concordantwithstudiesinsimilarpatient
populations (8,11). Patients with a his-
tory of psychiatric illness (depression/
anxiety) were not excluded. Few serious
psychiatric adverse events occurred (one
case of suicidal ideation with rimon-
abant), consistent with previous studies
involving patients with a psychiatric ill-
ness history (14). The ARPEGGIO study
further supports the endocannabinoid
system as a therapeutic target for over-
weight and glycemia. Further evaluation
of this system is needed to achieve effec-
tive and well-tolerated agents.
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